Takeda Reports Higher H1 Core Earnings and Revenue, Lifts 2026 Guidance
Takeda Pharmaceutical reported higher first-half core earnings and revenue and lifted its 2026 guidance.
Related stories
Luxshare Precision Expects FY26 Net Profit to Rise 15%-20%
M impact | EARNINGS | Oct 30, 2026, 12:06 AM UTC
US Futures Drop on Disappointing Tech Earnings
US stock futures fell sharply on Friday as disappointing earnings from major technology companies dampened market sentiment. Nasdaq 100 futures dropped around 1.6%, while S&P 500 f
H impact | EARNINGS | Oct 30, 2026, 12:06 AM UTC
Luxshare Precision Industry 9-Month Net CNY13.06B
Luxshare Precision Industry reported net income of CNY13.06 billion for the first nine months, versus CNY11.52 billion.
M impact | EARNINGS | Oct 30, 2026, 12:02 AM UTC
Centerra Gold Expects 2026 All-In Sustaining Costs Within a 2026 Range
M impact | EARNINGS | Oct 30, 2026, 12:01 AM UTC
Centerra Gold Forecasts 2026 All-In Sustaining Costs at $1,650-$1,750 per Ounce
M impact | EARNINGS | Oct 30, 2026, 12:01 AM UTC
First Northern Community Bancorp Reports Q3 2026 Net Income of $6.2 Million
M impact | EARNINGS | Oct 29, 2026, 11:59 PM UTC